Determinants of tobacco cessation among patients with chronic diseases (diabetes/hypertension) enrolled in Ministry of Health Tobacco Cessation Clinics, Kingdom of Saudi Arabia from 2012-2017

A case control study

Nariman A. Alshakhis, MBSS, SBCM, Mahmoud A. Mahmoud, MD, ABCM, Ali M. Alwadey, MBSS, FETP

ABSTRACT

Objectives: To investigate factors associated with tobacco cessation among patients with diabetes or hypertension who had been abstinence from tobacco for at least 6 months after attending MOH tobacco cessation clinics. Controls were patients with chronic diseases who had not quit tobacco after cessation clinics. Data were collected through a questionnaire by telephone interviews. Descriptive analysis, bivariate analysis, and multivariable regression were carried out.

Results: Overall, 85 (21.1%) respondents had successfully quit tobacco, while 317 (78.9%) had not. Among those who had not quit cigarettes, 97 (42.4%) had reduced cigarette consumption, the mean difference in cigarette smoking before to after MOH TCC was 0.81±5.928 (95% confidence interval [CI]: 2.584-1.040). Most of those who used other forms of tobacco 16 (72.7%) had not changed their consumption. The likelihood of successfully quitting tobacco increased with those lower educational level (adjusted odds ratio [AOR]=17.01, 95% CI: 1.00-289.2, p=0.05) and among those who reported controlled hypertension (AOR=17.8, 95% CI: 1.5-209.6, p=0.02).

Conclusion: To increase abstention rates, chronic disease counseling with regular follow-ups, providing toll-free telephone services should be considered. More effort is needed to reduce non-cigarette tobacco consumption.

Keywords: tobacco, cessation, DM, hypertension, Saudi Arabia

Original Article

Saudi Med J 2021; Vol. 42 (4): 433-440
doi: 10.15537/smj.2021.42.4.20200354

From the Ministry of Health (Alshakhis), Dammam; from the Department of Community and Family Medicine (Mahmoud), Al Imam Mohammad Ibn Saud Islamic University; and from the Anti-Tobacco Program (Alwadey), Ministry of Health, Riyadh; Kingdom of Saudi Arabia.

Received 18th November 2020. Accepted 23rd February 2021.

Address correspondence and reprint request to: Dr. Nariman A. Alshakhis, Ministry of Health, Dammam, Kingdom of Saudi Arabia.
E-mail: Nariman.alshakhis@hotmail.com
ORCID ID: https://orcid.org/0000-0002-1262-1141
Every year worldwide, 6 million premature deaths are attributed to tobacco use.1 Smoking has been identified as a modifiable risk factor for diabetes and hypertension.2 To reduce premature death in patients with non-communicable diseases, the World Health Organization (WHO) targets reduction of smoking prevalence to 30% by 2030.1

Saudi Arabia has one of the highest prevalence rates of diabetes,18.5% in 2017.3,4 Diabetic patients' economic burden on national healthcare is 10 times higher than that of non-diabetic patients,5 as the burden of treatment and complications is high.5 Additionally, in the last Saudi national health survey, 15.2% and 40.6% of Saudis respectively presented with hypertension or borderline hypertension.6 Thus, it is important to focus on modifiable risk factors for both these conditions.

Tobacco use in Saudi Arabia has changed over the past years. In 2010, the WHO estimated around 16% of Saudi Arabia's population smoked (26% of men and 3% of women). The highest smoking rate corresponded to the 25-39 age group among men (27.4%) and the 70 and above age group among women (4.2%).1 If we compare prevalence between the 2005 Stepwise Approach Survey and the 2013 national health survey, smoking decreased in the 15-24 age group, (men: 25.9% to 16.1%; women: 1.0% to 0.8%) and prevalence increased from 12.2% to 15.3% in the 25-64 age group.7,8 Approximately half of Saudi smokers who attempted quitting reported failing to abstain in the last 12 months, although no information is available on their enrollment into a tobacco cessation program.8 Few studies have reported on quitting rates among smokers in Saudi Arabia.8-10

In the literature, certain factors are associated with smoking cessation in the general population, such as late age initiation of smoking, low nicotine dependence, previous successful long-term quitting attempts.11 Yet, few studies have reported on determinants of cessation among those diagnosed with diabetes or hypertension.12,13 A recent study on chronic illness and smoking cessation reported that diabetics were more likely to quit than individuals with hypertension.12 Similarly, a diabetes-specific 30-minute counseling session was efficacious in India.13 Other studies have indicated that an inpatient cessation program was more effective than an outpatient program.14

In 2008, the WHO introduced tobacco control measures.15 Saudi Arabia has long been involved in tobacco use prevention and cessation promotion. In 2002, a Tobacco Control Program affiliated with the Ministry of Health (MOH) was established.16 The program employs approximately 100 full-time staff and runs over 70 clinics offering free services. Physicians offer behavioral therapy and medication, including nicotine replacement therapy, varenicline, and bupropion. The government covers all medication. Medications are also sold in pharmacies without prescriptions, except for varenicline and bupropion. Yet no toll-free telephone quitting line is currently available.17

Practices to aid tobacco cessation are usually generalized to all users.18 Individuals with diabetes or hypertension are pressured to change their lifestyle to reduce the risk of associated complications, but facilitating tobacco cessation in this population may require a more tailored approach.19 The WHO projects the Kingdom will likely not achieve the smoking component of the global non-communicable disease targets (if adopted by the Saudi government) based on current smoking trends.3 However, most studies carried out in Saudi Arabia investigating determinants of tobacco cessation targeted the general population as a sample instead of patients with chronic-disease attending MOH Tobacco Cessation Clinics (TCCs). Our objective was to investigate the nature of those factors and estimate tobacco cessation rates in MOH TCC users according to those factors to provide clinicians and public health workers more knowledge upon which to modify their clinical approaches and increase tobacco cessation rates among chronic-disease patients.

Methods. A case control study with 402 respondents was carried out. Data collection took place in Riyadh, Saudi Arabia between January 2018 to April 2018. The Institutional Review Board was obtained from King Fahad Medical City, Riyadh, Saudi Arabia. We employed Saudi guidelines for tobacco cessation services to define cases and controls.20 Tobacco cessation is defined as when a tobacco user quits all forms of tobacco use for at least 6 consecutive months. Based on that definition, cases were respondents with chronic disease (diabetes/hypertension) who had abstained all forms of tobacco use for at least 6 months after attending a MOH TCC. Abstinence was based on self-report and calculated based on the length of time between the last tobacco use date and the telephone call date. Controls were defined as respondents with chronic disease who did not quit all forms of tobacco use.

Disclosure. Authors have no conflict of interests, and the work was not supported or funded by any drug company.
consumption for at least 6 months even after attending the TCC.

The inclusion criteria accommodated participants with diabetes, hypertension, or comorbid diabetes and hypertension; Saudi or non-Saudi; aged above 40 at the time of the study; adhering to clinic follow-up for 6 months or more (from the date of first visit to the date of the telephone call); and enrolled at TCC between January 2012 and May 2017. We excluded any participant in the TCC database without a contact telephone number or information on key variables. Our study was conducted in accordance with the principles of Helsinki Declaration.

Telephone numbers of patients who attended TCCs were obtained from the Tobacco Control Management System, a database containing program patient information. Ten interviewers telephoned these patients and explained the study aim and questionnaire content. Patients who answered the phone and were willing to participate were asked to answer the questionnaire; those who did not answer were called twice more and were excluded if there was no subsequent response. Interviewers were trained to fill out the questionnaire and administer phone interviews with a protocol providing a structured method for how to initiate the phone call, explain study aims, ask questions, and answer possible participant enquiries.

Assuming an odds ratio (OR) of 0.64, power of 80%, alpha of 5%, and precision of 5%, the required sample size was 362, and final sample size was 402 (adjusting for 10% non response rate). The OR was selected based on previous tobacco cessation studies. In one study, various factors were estimated, and employment was adopted, which was significantly associated with successful cessation (OR of 0.62 indicated employed smokers had higher cessation rates than unemployed).\textsuperscript{21} Odd ratio choice ensured the largest sample size among the factors considered.

The questionnaire comprised 7 sections. The first section recorded the participant’s basic information: phone call date and participant contact number. They were assigned a code for the current study. The second section inquired on screening: current age, date of first and last TCC visit, and diagnosis of diabetes, hypertension, or both. For participants who could not recall the dates, we obtained them from the tobacco control management system to ensure at least 6 months of follow-up. The third section covered sociodemographic characteristics: participant’s age, marital status, highest education level, current occupation, monthly income, and geographical region of MOH TCC follow-up. The fourth section covered the patient’s chronic disease history: total years diagnosed with the chronic disease, the usual clinic for disease follow-up and number of visits, level of control over the chronic disease, hospitalization history, hospital admission reasons, and if the treating physician had recommended tobacco cessation. Level of diabetes control was based on American Diabetes Association Guidelines:\textsuperscript{22} participants who reported having last hemoglobin A1c (HgA1c) level of over 7% were considered to have uncontrolled diabetes mellitus (DM), while participants who reported having last HgA1c level under 7% were considered to have controlled DM. Hemoglobin A1c level was measured based on participant self-reports. Level of hypertension control was based on Saudi guidelines:\textsuperscript{23} participants who reported last blood pressure reading over 130/80 mm/Hg were considered to have uncontrolled hypertension, and those whose last blood pressure reading was under 130/80 mm/Hg were considered to have controlled hypertension. Nicotine dependence was assessed by asking participants to report their nicotine dependence level at their first visit to the clinic. The fifth section concerned current tobacco use; if not currently using tobacco, we inquired on the participants’ last tobacco use date, and abstinence was calculated from the last tobacco use date to the telephone call date. Participants were asked their perceived reason for success. Current tobacco users were asked regarding the type of tobacco they consumed, frequency of use, number of packs consumed weekly (for cigarette smokers), and (for other users) the amount of tobacco they consumed (daily consumption or less than daily) and perceived reason for failure to quit. The sixth section concerned participants’ history of tobacco use: age of first tobacco use, tobacco type and frequency of use before TCC, earlier attempts to quit, and quitting methods used before attending the MOH TCC. The last section covered the services participants had received from the MOH TCC: how they found the clinic, number of visits, treatment type received, medications prescribed, duration (days) of medication use, and overall satisfaction level with provided services.

Participant consent was taken by phone. Participants’ anonymity was assured by assigning each participant a code number for analysis purpose only. Participants received no incentives or rewards.

\textbf{Statistical analysis.} The research team was responsible for recording and verifying participants’ data entered by the phone interviewer. Data were tabulated and analyzed using Statistical Package for Social Sciences, version 21 (IBM Corp, Armonk, NY, USA). Both descriptive and analytic inferential statistics were conducted. Categorical variables were presented as
counts and proportions (%), and continuous variables were given as mean ± standard deviation. Results were presented as percentages with a 95% CI for smoking cessation. Factors associated with successful smoking cessation were evaluated in a bivariate analysis, and results were presented as OR with 95% CI. Chi-square and univariate analysis were used for comparison and correlation between variables of interest versus other categorical variables. We used Chi-square test to evaluate the association between demographic variables against the group of respondents as case (those who quit all forms of tobacco at least for 6 months and more after attending MOH TCC) versus control (those who fail to quit all forms of tobacco at least for 6 months and more after attending MOH TCC) with p-values which indicates whether the association was statistically significant. P-value of ≤ 0.05 has been accepted as the level of significance. A multivariate analysis was conducted as well, again with OR and 95% CI. A p-value of ≤ 0.05 was used as the significance level for all the statistical tests.

**Results.** A total of 769 potential participants were contacted; 402 were included in the sample, 275 did not respond, and 92 were excluded. The response rate was 64.2%. The majority of respondents had not quit tobacco (78.9%), while 85 (21.1%) had successfully quit all forms of tobacco for 6 months and more after attending MOH TCC. Tables 1-3 presents descriptive analysis of respondents’ sociodemographic, chronic disease characteristic, and received medical services.

**Harm reduction.** Among those who were currently using cigarettes, 97 (42.4%) were able to reduce cigarette consumption after attending MOH TCC, 91 (39.7%) were not able to quit, while 41 (17.9%) increased cigarette consumption. The mean difference in cigarette smoking from before to after MOH TCC was -0.182 ± 5.928 (95% CI: 2.584-1.040). Among those currently using alternative forms of tobacco, most could not alter tobacco consumption after the MOH TCC (n=16, 72.7%), while, 5 (22.7%) of these increased tobacco consumptions after the MOH TCC and only 1 (4.5%) could reduce tobacco consumption.

Table 4 presents Chi-square results of sociodemographic characteristics and respondents’ quit status. The Chi-square tests showed that all sociodemographic characteristics included in the table had no significant relationship to respondent quit status. After controlling for sociodemographic factors, the likelihood of successfully quitting tobacco increased with lower educational level (adjusted OR [AOR]=17.01, 95% CI: 1.00-289.2, p=0.050) and among those who had controlled hypertension (AOR=17.824, 95% CI: 1.516-209.6, p=0.022), Table 5.

**Discussion.** Our study found almost a quarter of participants who received care from the MOH TCC could remain abstinent from tobacco for 6 months or
Determinants of tobacco cessation ... Alshakhis et al

Table 2 - Chronic disease characteristic of respondents’ attending Ministry of Health (MOH) Tobacco Cessation Clinics, Riyadh, Saudi Arabia, 2012-2017.

| Characteristics                      | Results          |
|--------------------------------------|------------------|
| Chronic diseases (n=402)              |                  |
| Only diabetes mellitus (DM)           | 384 (95.5)       |
| Only hypertension (HTN)               | 193 (48.0)       |
| Both                                 | 175 (43.5)       |
| Duration of DM (n=377)                |                  |
| ≤10 years                            | 235 (62.7)       |
| >10 years                            | 140 (37.3)       |
| Missing-25                           |                  |
| Duration of HTN (n=192)               |                  |
| ≤10 years                            | 135 (70.7)       |
| >10 years                            | 56 (29.3)        |
| Missing-140                          |                  |
| Type of clinic visited for medical care of DM or HTN (n=351) |          |
| MOH-primary health care               | 175 (45.7)       |
| MOH-hospital                          | 103 (26.9)       |
| Private hospital                      | 69 (18.0)        |
| Other government hospital             | 74 (19.3)        |
| None                                 | 19 (04.7)        |
| Missing-210                          |                  |
| Frequency of health care facility visit per year for DM follow up (n=351) |          |
| ≤8 times per year                    | 199 (56.7)       |
| >8 times per year                    | 152 (43.3)       |
| Frequency of health care facility visit per HTN follow up (n=165) |          |
| ≤8 times per year                    | 88 (53.3)        |
| >8 times per year                    | 77 (46.7)        |
| Reported level of DM control (n=402)  |                  |
| Controlled                            | 60 (16.1)        |
| Uncontrolled                          | 126 (33.9)       |
| Don’t know                            | 216 (53.7)       |
| Missing-216                           |                  |
| Reported level of HTN control (n=402) |                  |
| Controlled                            | 28 (07.0)        |
| Uncontrolled                          | 48 (11.9)        |
| Don’t know                            | 326 (81.1)       |
| Last reported HbA1c (n=186) (mean±SD) | 07.7±0.17       |
| Missing-216                           |                  |
| Last known systolic blood pressure (n=81) (mean±SD) | 143.9±27.9      |
| Last known diastolic blood pressure (n=76) (mean±SD) | 87.4±21.6       |
| Previous Hospital Admission (n=392)   |                  |
| Yes                                  | 65 (16.6)        |
| No                                   | 327 (83.4)       |
| Missing-10                           |                  |
| Reason for hospital admission (n=402) |                  |
| Thromboembolism                       | 13 (27.1)        |
| High blood sugar                      | 10 (20.8)        |
| High blood pressure                   | 04 (08.3)        |
| Heart disease                         | 10 (20.8)        |
| Other disease                         | 11 (22.9)        |
| Treating physician recommended tobacco cessation (n=381) |          |
| Yes                                  | 305 (80.1)       |
| No                                   | 76 (19.9)        |
| Missing-21                            |                  |
| Self-decision to quit tobacco due to DM or HTN (n=398) |          |
| Yes                                  | 179 (45.0)       |
| No                                   | 219 (55.0)       |
| Missing-4                            |                  |

Table 3 - Medical Services provided to respondents with chronic diseases (diabetes/hypertension) attending Ministry of Health Tobacco Cessation Clinics, Riyadh, Saudi Arabia, 2012-2017.

| Characteristics                      | Results          |
|--------------------------------------|------------------|
| Type of treatment                    |                  |
| Behavioral                           | 186 (46.3)       |
| Medications                          | 371 (92.3)       |
| Both                                 | 166 (41.3)       |
| Type of medication (n=352)           |                  |
| Patch                                | 156 (38.8)       |
| Tablets                              | 262 (65.2)       |
| Gum                                  | 11 (02.7)        |
| Lozenge                              | 68 (16.9)        |
| Type of tablet (n=262)               |                  |
| Varenicline                          | 233 (58.0)       |
| Bupropion                            | 04 (01.0)        |
| Missing-23                           |                  |
| Days used medication (means±SD)      |                  |
| Days for patch                       | 22.6 ± 30.9      |
| Days for lozenges                    | 31.9 ± 98.8      |
| Days for varenicline                 | 38.9 ± 48.9      |
| Days for bupropion                   | 15.0 ± 17.3      |
| Days for gum                         | 10.0 ± 0         |
| Treatment satisfaction (n=352)       |                  |
| Very unsatisfied                     | 17 (04.8)        |
| Unsatisfied                          | 26 (07.4)        |
| Unsure                               | 45 (12.8)        |
| Satisfied                            | 121 (34.4)       |
| Very satisfied                       | 143 (40.6)       |
| Missing-50                           |                  |

Values are presented as mean ± standard deviation, number and percentage (%).

more (n=85, 21.1%). Additionally, among those who did not quit cigarettes, 97 (42.4%) were able to reduce their consumption. The mean difference in cigarette smoking from before to after MOH TCC was 01.812 ± 5.928 (95% CI: 2.584-1.040). While the majority (72.7%) of those using other tobacco forms (other than cigarettes) could not reduce tobacco consumption. The most significant factors predicting tobacco cessation were lower level of education and controlled hypertension. Although respondents provided good satisfaction rate on services they received, yet the majority attended the clinic 1-3 times only 345 (87.3%). Saudi guidelines for tobacco cessation services recommends at least 6 visits, with weekly follow up for one month after cessation and monthly telephone follow up for 6 months.

We compared our results with the last national tobacco survey, although this survey neither targeted chronic disease patients nor considered if participants quit tobacco through any program. Our finding is similar to the survey, in which 25.3% of the sample had successfully quit smoking at the time of survey and of them, 41.3% had at least a year of abstinence. The only
other study carried out in Saudi Arabia that evaluated general population tobacco cessation after specialized program attendance indicated an abstinence rate of 38.3% for at least 6 months.\textsuperscript{21} One possible explanation that our quit rate is lower than this result is because the previous study’s population was generally younger, as they were not sampling patients with chronic diseases. Indeed, the reported mean age for successful cessation in that study was younger than that of smokers who continued smoking (22.98 ± 5.66 years and 27.07 ± 9.33 years, respectively). A systematic review of patients with diabetes revealed more intensive programs were more effective than less intensive programs (relative risk 1.32).\textsuperscript{24} Studies mentioning specific interventions for chronic disease patients have shown higher cessation rates than studies with less intensive interventions. For instance, 2 randomized controlled studies in India\textsuperscript{25} and Indonesia\textsuperscript{26} showed that adding diabetes-specific tobacco counseling increased cessation odds. In India, those whose doctors advised quitting and who received specific 30-minute diabetes counseling by a non-doctor had a higher cessation rate (52%) after 6 months than those who only received quitting advice.\textsuperscript{25} In Indonesia, those who received doctor advice and education had a quit rate of 30% versus 37% for those who received doctor advice plus cessation clinic referral.\textsuperscript{26} Conversely, another randomized tobacco trial using diabetic patients showed that adding moderate-intensity education sessions by a trained nurse and educational leaflets had no effect after 6 months of follow-up compared to those who received usual care.\textsuperscript{27} Evidently, there is much heterogeneity in defining less and more intense interventions. The most recent systematic review on smoking cessation interventions for diabetics mentioned that more intense interventions used medications plus diabetes-specific counseling.\textsuperscript{25} As far as we know, MOH TCC uses behavior therapy and medication with all smokers; no specific counseling targets those with chronic diseases. Studying customized approaches for tobacco cessation in patients with chronic diseases could be studied in future researches. Our results showed that those using other tobacco forms could not
quit and the last national tobacco survey mentioned increase in shisha use in both men and women in all age groups: men: 3.3% (STEPwise study) to 7.4%; women aged 15 to 64 years: 0.5% to 1.3%.8 We recommend physicians working in chronic disease clinic to do reinforcement of cessation messages during follow-up visits and inform them regarding MOH TCC services.

**Study limitations.** Our study might be affected by interviewer bias since we had multiple data collectors. The study was also limited by recall bias, the fact that the findings were based on self-report and not objectively measured-in particular those on abstinence and on blood pressure and HgA1c. We only included those who had diabetes and hypertension and did not include other chronic diseases, this might have caused some bias. We had a lot of missing data and the data was not normally distributed. There were few studies to compare with locally and internationally in the topic of tobacco cessation in patients with hypertension and diabetes.

In conclusion, to increase abstention rates, methods like specific behavioral therapy for chronic disease patients counseling with regular follow-ups, informing patients of tobacco cessation clinic services, and providing toll-free telephone services should be considered. More effort is needed to reduce non-cigarette tobacco consumption.

**Acknowledgment.** We would like to acknowledge Editage (www.editage.com) for providing English language editing.

**References**

1. World Health Organization. WHO Global Report On Trends in Prevalence of Tobacco Smoking 2015. [Updated 2015; Accessed 2017 December 5]. Available from URL: https://apps.who.int/iris/bitstream/handle/10665/156262/9789241564922_eng.pdf?jsessionid=74CC01BA60893520314E63FA90578956?sequence=1
2. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The health consequences of smoking—50 years of progress. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014.
3. Naeem Z. Burden of diabetes mellitus in Saudi Arabia. *Int J Health Sci (Qassim)* 2015; 9: 5-6.
4. International Diabetes Federation. IDF MENA Members. [Updated 2020 February 25. Cited 2020 June 9]. Available from URL: https://www.idf.org/our-network/regions-members/middle-east-and-north-africa/members/46-saudi-arabia.html
5. Alhowaish AK. Economic costs of diabetes in Saudi Arabia. *J Family Community Med* 2013; 20: 1-7.
6. El Bcheraoui C, Memish ZA, Tuffaha M, Daoud F, Robinson M, Jaber S, et al. Hypertension and its associated risk factors in the Kingdom of Saudi Arabia, 2013: A national survey. *Int J Hypertens* 2014; 2014: 564679.
7. Ministry of Health, World Health Organization. WHO STEPwise Approach to NCD Surveillance. Country-Specific Standard Report: Saudi Arabia 2005. [Updated 2005; Accessed 2017 December 5]. Available from URL: https://www.who.int/ncds/surveillance/steps/2005_SaudiArabia_STEPS_Report_EN.pdf
8. Moradi-Lakeh M, El Bcheraoui C, Tuffaha M, Daoud F, Al Saeedi M, Basulaiman M, et al. Tobacco consumption in the Kingdom of Saudi Arabia, 2013: Findings from a national survey. *BMC Public Health* 2014; 15: 611.
9. Bassiony MM. Smoking in Saudi Arabia. *Saudi Med J* 2009; 30: 876-881.
10. Al-Mohrej O, Al-Shirian S, Altraif S, Tamim H, Fakhoury H. What encourages Saudis to quit smoking? *J Health Spec* 2016; 4: 146-150.
11. Yang JJ, Song M, Yoon HS, Lee HW, Lee Y, Lee SA, et al. What are the major determinants in the success of smoking cessation: results from the health examinees study. *PLoS One* 2015; 10: e0143303.
12. Patel K, Schlundt D, Larson C, Wang H, Brown A, Hargreaves M. Chronic illness and smoking cessation. *Nicotine Tob Res* 2009; 11: 933-999.
13. Thankappan KR, Mini GK, Daivadamam M, Vijayanumar G, Sarma PS, Nichert M. Smoking cessation among diabetes patients: Results of a pilot randomized controlled trial in Kerala, India. *BMC Public Health* 2013; 13: 47.
14. Kim SH, Lee JA, Kim KU, Cho HJ. Results of an inpatient smoking cessation program: 3-month cessation rate and predictors of success. *Korean J Fam Med* 2015; 36: 50-59.
15. World Health Organization. Enforcing bans on tobacco advertising, promotion and sponsors. [Updated 2013. Cited 2019 June 9]. Available from URL: http://apps.who.int/iris/bitstream/handle/10665/85380/9789241505871_eng.pdf?jsessionid=7DBE7040583E828E7AFB9475C4A6D48?sequence=1
16. Ministry of Health, Saudi Arabia. Tobacco Control Program. [Updated 2017; Accessed 2018 May 9]. Available from URL: https://www.moh.gov.sa/depten/TCP/Pages/About.aspx
17. World Health Organization. WHO report on the global tobacco epidemic 2017. [Updated 2017; Accessed 2018 May 9]. Available from URL: https://www.who.int/tobacco/global_report/2017/en/
18. Asif M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. *J Educ Health Promot* 2014; 3: 1.
19. Bohlen K, Scoville E, Shippee ND, May CR, Montori VM. Overwhelmed patients: 443 A videographic analysis of how patients with type 2 diabetes and clinicians articulate and 444 address treatment burden during clinical encounters. *Diabetes Care* 2012; 35: 47-49.
20. Ministry of Health. Saudi Guideline For Smoking Cessation Services. [Updated 2018. Cited 2019 June 9]. Available from URL: http://www.tcpmoh.gov.sa/media/Docs/cef3b048-75ef-4b86-b0bf-d50f9088a64.pdf
21. Salih MA, Farghaly AA. Determinants of outcome among smokers in a smoking 416 cessation program. *J Family Community Med* 1996; 3: 22-31.
Determinants of tobacco cessation ... Alshakhis et al

22. American Diabetes Association. Standards of medical care in diabetes2017. Abridged for primary care providers. Clin Diabetes 2017; 35: 5-26.
23. Saudi Hypertension Management Society and Saudi Commission for Health Specialities. Saudi Hypertension Guidelines 2018. [Updated 2018; Accessed 2018 June 11]. Available from URL: http://shms.wildapricot.org/resources/Guidelines/Saudi Hypertension Guideline 2018_8Feb18.pdf
24. Nagrebetsky A, Brettell R, Roberts N, Farmer A. Smoking cessation in adults with diabetes: A systematic review and meta-analysis of data from randomised controlled trials. BMJ Open 2014; 4: e004107.
25. Thresia CU, Thankappan KR, Nichter M. Smoking cessation and diabetes control in Kerala, India: An urgent need for health education. Health Educ Res 2009; 24: 839-845.
26. Ng N, Nichter M, Retna Siwi Padmawati RS, Prabandari YS, Muramoto M, Nichter M. Bringing smoking cessation to diabetes clinics in Indonesia. Chronic Illn 2010; 6: 125-135.
27. Li WHC, Wang P, Lam TH, Yannes TYC, Derek YTC, Suen YN, et al. Brief intervention to promote smoking cessation and improve glycemic control in smokers with type 2 diabetes: a randomized controlled trial. Sci Rep 2017; 7: 45902.